Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
- Mechanism
- Curator reviewed
Denibulin selectively disrupts newly-formed tumor blood vessels, shutting down tumor blood flow and causing central necrosis of solid tumors. Consistent with its proposed mechanism of action, denibulin has been shown to reduce tumor blood flow resulting in tumor cell necrosis in rats bearing a human lung tumor xenograft. The present Phase I study now extends these findings (reductions in tumor blood flow) to cancer patients.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Formula / weight
- C18H19N5O3S · 385.44 g/mol (avg)
- Code names
- MN-029
Resolves to
GAOHLWCIAJNSEE-JTQLQIEISA-NSMILESCOC(=O)NC1=NC2=C(N1)C=CC(SC1=CC=C(NC(=O)[C@H](C)N)C=C1)=C2What you can answer from here — as of September 16, 2026
Which drugs share a target with Denibulin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account